Life science company ProImmune has announced a collaboration with The University of Texas Medical Branch (UTMB) to partner on research into infectious diseases. The collaboration will combine ProImmune’s Ankyron target binding reagent technology with expertise at the Galveston National Laboratory (GNL), part of UTMB, in the immunopathology of emerging viruses. Under the… Read More
Biotechnology company Circio Holding is set to collaborate with The University of Texas Medical Branch (UTMB) to evaluate treatments for infectious diseases. The partnership aims to design and test Circio’s circVEC technology for the prevention and treatment of infections, cancer and gene therapy. The technology allows for the long-term expression of proteins, protecting against… Read More
The University of Texas MD Anderson Cancer Center has been awarded $20 million to strengthen neurodegeneration research. The donation was awarded to the Belfer Neurodegeneration Consortium (BNDC), which aims to develop five new medicines for Alzheimer’s disease and related disorders over the next 10 years, with… Read More
